Skip to main content
Erschienen in: Cancer Causes & Control 4/2006

01.05.2006 | Special Section on Cancer and Rhythm

Circulating Melatonin Levels: Possible Link Between Parkinson’s Disease and Cancer Risk?

verfasst von: Eva Schernhammer, Honglei Chen, Beate Ritz

Erschienen in: Cancer Causes & Control | Ausgabe 4/2006

Einloggen, um Zugang zu erhalten

Abstract

Lower rates of cancer mortality/incidence in patients with Parkinson’s disease (PD) have given rise to speculations about risk or preventative factors common to both diseases, including life-style factors (such as smoking) and genetic susceptibility. Melatonin, a hormone known for its sleep regulatory effects, may play an important role in carcinogenesis as suggested by substantial laboratory and less direct epidemiologic evidence. Particularly, a reduction in melatonin, such as experienced by persons who are exposed to light at night, appears to increase cancer risk. Variations in melatonin levels have been linked to PD in several different ways. Some studies show higher morning melatonin levels in PD patients than in healthy controls. One could speculate that the sleep disorders that affect almost two thirds of those suffering from PD and can precede PD motor symptoms by several years may be associated with variations in melatonin levels. Moreover, in animal models, interventions that increase the bioavailability of melatonin appears to increase the severity of parkinsonian symptoms, whereas reduction in melatonin by pinealectomy or exposure to bright light can enhance recovery from parkinsonisms symptoms. Finally, preliminary epidemiological evidence suggests that longer years of working night shifts is associated with a reduced risk of PD among participants of the Nurses’ Health Study (NHS), whereas longer hours of sleep appear to increase their risk. In sum, while lower melatonin concentrations may predict a higher cancer risk, there is also some evidence that they may be associated with a lower risk of PD. We therefore hypothesize that elevated circulating melatonin levels in PD patients may contribute to their lower cancer rates.
Literatur
1.
Zurück zum Zitat Barbeau A, KJoly JG (1963) Parkinsonism et cancer. Union Med Can 92:169–174PubMed Barbeau A, KJoly JG (1963) Parkinsonism et cancer. Union Med Can 92:169–174PubMed
2.
Zurück zum Zitat Ben-Shlomo Y, Marmot MG (1995) Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 58:293–299PubMed Ben-Shlomo Y, Marmot MG (1995) Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 58:293–299PubMed
3.
Zurück zum Zitat Gorell JM, Johnson CC, Rybicki BA (1994) Parkinson’s disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology 44:1865–1868PubMed Gorell JM, Johnson CC, Rybicki BA (1994) Parkinson’s disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology 44:1865–1868PubMed
4.
Zurück zum Zitat Harada H, Nishikawa S, Takahashi K (1983) Epidemiology of Parkinson’s disease in a Japanese city. Arch Neurol 40:151–154PubMed Harada H, Nishikawa S, Takahashi K (1983) Epidemiology of Parkinson’s disease in a Japanese city. Arch Neurol 40:151–154PubMed
5.
Zurück zum Zitat Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. 1967.Neurology 57:S11–S26 Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. 1967.Neurology 57:S11–S26
6.
Zurück zum Zitat Jansson B, Jankovic J (1985) Low cancer rates among patients with Parkinson’s disease. Ann Neurol 17:505–509CrossRefPubMed Jansson B, Jankovic J (1985) Low cancer rates among patients with Parkinson’s disease. Ann Neurol 17:505–509CrossRefPubMed
7.
Zurück zum Zitat Pritchard PBr, Netsky MG (1973) Prevalence of neoplasms and causes of death in paralysis agitans. A necropsy study.Neurology 23:215–222PubMed Pritchard PBr, Netsky MG (1973) Prevalence of neoplasms and causes of death in paralysis agitans. A necropsy study.Neurology 23:215–222PubMed
8.
Zurück zum Zitat Rajput AH, Offord KP, Beard CM, Kurland LT (1987) A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson’s disease. Neurology 37:226–232PubMed Rajput AH, Offord KP, Beard CM, Kurland LT (1987) A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson’s disease. Neurology 37:226–232PubMed
9.
Zurück zum Zitat Westlund K (1956) Cancer as a cause of death among patients with other chronic diseases. JAMA 162:1003 Westlund K (1956) Cancer as a cause of death among patients with other chronic diseases. JAMA 162:1003
10.
Zurück zum Zitat Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S (2000) Mortality and cancer incidence in patients with Parkinson’s disease.J Neurol 247:429–434CrossRefPubMed Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S (2000) Mortality and cancer incidence in patients with Parkinson’s disease.J Neurol 247:429–434CrossRefPubMed
11.
Zurück zum Zitat Elbaz A, Peterson BJ, Yang P, et al. (2002) Nonfatal cancer preceding Parkinson’s disease: a case-control study. Epidemiology 13:157–164CrossRefPubMed Elbaz A, Peterson BJ, Yang P, et al. (2002) Nonfatal cancer preceding Parkinson’s disease: a case-control study. Epidemiology 13:157–164CrossRefPubMed
12.
Zurück zum Zitat Rostami-Hodjegan ALM, Woods HF, Tucker GT (1998) Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson’s disease. Pharmacogenetics 8:227–238PubMed Rostami-Hodjegan ALM, Woods HF, Tucker GT (1998) Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson’s disease. Pharmacogenetics 8:227–238PubMed
13.
Zurück zum Zitat Morens DM GA, Davis JW, Ross GW, White LR, Reed D (1996) Evidence against the operation of selective mortality in explaining the association between cigarette smoking and reduced occurrence of idiopathic Parkinson disease.Am J Epidemiol 144:400–404PubMed Morens DM GA, Davis JW, Ross GW, White LR, Reed D (1996) Evidence against the operation of selective mortality in explaining the association between cigarette smoking and reduced occurrence of idiopathic Parkinson disease.Am J Epidemiol 144:400–404PubMed
14.
Zurück zum Zitat Elbaz A, Bower JH, Peterson BJ, et al. (2003) Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol 60:91–96PubMed Elbaz A, Bower JH, Peterson BJ, et al. (2003) Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol 60:91–96PubMed
15.
Zurück zum Zitat Vanacore N, Spila-Alegiani S, Raschetti R, Meco G (1999) Mortality cancer risk in parkinsonian patients: a population-based study.Neurology 52:395–398PubMed Vanacore N, Spila-Alegiani S, Raschetti R, Meco G (1999) Mortality cancer risk in parkinsonian patients: a population-based study.Neurology 52:395–398PubMed
16.
Zurück zum Zitat Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H (2005) Atypical cancer pattern in patients with Parkinson’s disease. Br J Cancer 92:201–205CrossRefPubMed Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H (2005) Atypical cancer pattern in patients with Parkinson’s disease. Br J Cancer 92:201–205CrossRefPubMed
17.
Zurück zum Zitat Jenner P (1998) Oxidative mechanisms in nigral cell death in Parkinson’s disease. Mov Disord 13:24–34PubMed Jenner P (1998) Oxidative mechanisms in nigral cell death in Parkinson’s disease. Mov Disord 13:24–34PubMed
18.
19.
Zurück zum Zitat Zhang SM, Hernan MA, Chen H, Spiegelman D, Willett WC, Ascherio A (2002) Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 59:1161–1169PubMed Zhang SM, Hernan MA, Chen H, Spiegelman D, Willett WC, Ascherio A (2002) Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 59:1161–1169PubMed
20.
Zurück zum Zitat Leon J, Acuna-Castroviejo D, Sainz RM, Mayo JC, Tan DX, Reiter RJ (2004) Melatonin and mitochondrial function. Life Sci 75:765–790CrossRefPubMed Leon J, Acuna-Castroviejo D, Sainz RM, Mayo JC, Tan DX, Reiter RJ (2004) Melatonin and mitochondrial function. Life Sci 75:765–790CrossRefPubMed
21.
Zurück zum Zitat Mayo JC, Sainz RM, Uria H, Antolin I, Esteban MM, Rodriguez C (1998) Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson’s disease.J Pineal Res 24:179–192PubMed Mayo JC, Sainz RM, Uria H, Antolin I, Esteban MM, Rodriguez C (1998) Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson’s disease.J Pineal Res 24:179–192PubMed
22.
Zurück zum Zitat Reiter RJ, Guerrero JM, Escames G, Pappolla MA, Acuna-Castroviejo D (1997) Prophylactic actions of melatonin in oxidative neurotoxicity. Ann N Y Acad Sci 825:70–78PubMed Reiter RJ, Guerrero JM, Escames G, Pappolla MA, Acuna-Castroviejo D (1997) Prophylactic actions of melatonin in oxidative neurotoxicity. Ann N Y Acad Sci 825:70–78PubMed
23.
Zurück zum Zitat Reiter RJ, Tan DX, Mayo JC, Sainz RM, Leon J, Czarnocki Z (2003) Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. Acta Biochim Pol 50:1129–1146PubMed Reiter RJ, Tan DX, Mayo JC, Sainz RM, Leon J, Czarnocki Z (2003) Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. Acta Biochim Pol 50:1129–1146PubMed
24.
Zurück zum Zitat Absi E, Ayala A, Machado A, Parrado J (2000) Protective effect of melatonin against the 1-methyl−4-phenylpyridinium-induced inhibition of complex I of the mitochondrial respiratory chain. J Pineal Res 29:40–47CrossRefPubMed Absi E, Ayala A, Machado A, Parrado J (2000) Protective effect of melatonin against the 1-methyl−4-phenylpyridinium-induced inhibition of complex I of the mitochondrial respiratory chain. J Pineal Res 29:40–47CrossRefPubMed
25.
Zurück zum Zitat Dabbeni-Sala F, Di Santo S, Franceschini D, Skaper SD, Giusti P (2001) Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J 15:164–170CrossRefPubMed Dabbeni-Sala F, Di Santo S, Franceschini D, Skaper SD, Giusti P (2001) Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J 15:164–170CrossRefPubMed
26.
Zurück zum Zitat Khaldy H, Escames G, Leon J, Vives F, Luna JD, Acuna-Castroviejo D (2000) Comparative effects of melatonin, L-deprenyl, Trolox and ascorbate in the suppression of hydroxyl radical formation during dopamine autoxidation in vitro. J Pineal Res 29:100–107CrossRefPubMed Khaldy H, Escames G, Leon J, Vives F, Luna JD, Acuna-Castroviejo D (2000) Comparative effects of melatonin, L-deprenyl, Trolox and ascorbate in the suppression of hydroxyl radical formation during dopamine autoxidation in vitro. J Pineal Res 29:100–107CrossRefPubMed
27.
Zurück zum Zitat Acuna-Castroviejo D, Coto-Montes A, Gaia Monti M, Ortiz GG, Reiter RJ (1997) Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 60:PL23–PL29PubMed Acuna-Castroviejo D, Coto-Montes A, Gaia Monti M, Ortiz GG, Reiter RJ (1997) Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 60:PL23–PL29PubMed
28.
Zurück zum Zitat Antolin I, Mayo JC, Sainz RM, et al. (2002) Protective effect of melatonin in a chronic experimental model of Parkinson’s disease. Brain Res 943:163–173PubMed Antolin I, Mayo JC, Sainz RM, et al. (2002) Protective effect of melatonin in a chronic experimental model of Parkinson’s disease. Brain Res 943:163–173PubMed
29.
Zurück zum Zitat Coulom H, Birman S (2004) Chronic exposure to rotenone models sporadic Parkinson’s disease in Drosophila melanogaster. J Neurosci 24:10993–10998CrossRefPubMed Coulom H, Birman S (2004) Chronic exposure to rotenone models sporadic Parkinson’s disease in Drosophila melanogaster. J Neurosci 24:10993–10998CrossRefPubMed
30.
Zurück zum Zitat Jin BK, Shin DY, Jeong MY, et al. (1998) Melatonin protects nigral dopaminergic neurons from 1-methyl−4-phenylpyridinium (MPP+) neurotoxicity in rats. Neurosci Lett 245:61–64CrossRefPubMed Jin BK, Shin DY, Jeong MY, et al. (1998) Melatonin protects nigral dopaminergic neurons from 1-methyl−4-phenylpyridinium (MPP+) neurotoxicity in rats. Neurosci Lett 245:61–64CrossRefPubMed
31.
Zurück zum Zitat Thomas B, Mohanakumar KP (2004) Melatonin protects against oxidative stress caused by 1-methyl−4-phenyl−1,2,3,6-tetrahydropyridine in the mouse nigrostriatum. J Pineal Res 36:25–32CrossRefPubMed Thomas B, Mohanakumar KP (2004) Melatonin protects against oxidative stress caused by 1-methyl−4-phenyl−1,2,3,6-tetrahydropyridine in the mouse nigrostriatum. J Pineal Res 36:25–32CrossRefPubMed
32.
Zurück zum Zitat Morgan WW, Nelson JF (2001) Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway.Brain Res 921:115–121CrossRefPubMed Morgan WW, Nelson JF (2001) Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway.Brain Res 921:115–121CrossRefPubMed
33.
Zurück zum Zitat van der Schyf CJ, Castagnoli K, Palmer S, Hazelwood L, Castagnoli NJ (2000) Melatonin fails to protect against long-term MPTP-induced dopamine depletion in mouse striatum.Neurotox Res 1:261–269PubMed van der Schyf CJ, Castagnoli K, Palmer S, Hazelwood L, Castagnoli NJ (2000) Melatonin fails to protect against long-term MPTP-induced dopamine depletion in mouse striatum.Neurotox Res 1:261–269PubMed
34.
Zurück zum Zitat Willis GL, Armstrong SM (1999) A therapeutic role for melatonin antagonism in experimental models of Parkinson’s disease. Physiol Behav 66:786–795CrossRef Willis GL, Armstrong SM (1999) A therapeutic role for melatonin antagonism in experimental models of Parkinson’s disease. Physiol Behav 66:786–795CrossRef
35.
Zurück zum Zitat Catala MD, Canete-Nicolas C, Iradi A, Tarazona PJ, Tormos JM, Pascual-Leone A (1997) Melatonin levels in Parkinson’s disease: drug therapy versus electrical stimulation of the internal globus pallidus. Exp Gerontol 32:553–558PubMed Catala MD, Canete-Nicolas C, Iradi A, Tarazona PJ, Tormos JM, Pascual-Leone A (1997) Melatonin levels in Parkinson’s disease: drug therapy versus electrical stimulation of the internal globus pallidus. Exp Gerontol 32:553–558PubMed
36.
Zurück zum Zitat Willis GL, Armstrong SM (1999) A therapeutic role for melatonin antagonism in experimental models of Parkinson’s disease.Physiol Behav 66:785–795CrossRefPubMed Willis GL, Armstrong SM (1999) A therapeutic role for melatonin antagonism in experimental models of Parkinson’s disease.Physiol Behav 66:785–795CrossRefPubMed
37.
Zurück zum Zitat Zisapel N (2001) Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cell Mol Neurobiol 21:605–616CrossRefPubMed Zisapel N (2001) Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cell Mol Neurobiol 21:605–616CrossRefPubMed
38.
Zurück zum Zitat Cos S, Fernandez F, Sanchez-Barcelo EJ (1996) Melatonin inhibits DNA synthesis in MCF−7 human breast cancer cells in vitro. Life Sci 58:2447–2453PubMed Cos S, Fernandez F, Sanchez-Barcelo EJ (1996) Melatonin inhibits DNA synthesis in MCF−7 human breast cancer cells in vitro. Life Sci 58:2447–2453PubMed
39.
Zurück zum Zitat Cos S, Fernandez R, Guezmes A, Sanchez-Barcelo EJ (1998) Influence of melatonin on invasive and metastatic properties of MCF−7 human breast cancer cells. Cancer Res 58:4383–4390PubMed Cos S, Fernandez R, Guezmes A, Sanchez-Barcelo EJ (1998) Influence of melatonin on invasive and metastatic properties of MCF−7 human breast cancer cells. Cancer Res 58:4383–4390PubMed
40.
Zurück zum Zitat Cos S, Mediavilla MD, Fernandez R, Gonzalez-Lamuno D, Sanchez-Barcelo EJ (2002) Does melatonin induce apoptosis in MCF−7 human breast cancer cells in vitro? J Pineal Res 32:90–96CrossRefPubMed Cos S, Mediavilla MD, Fernandez R, Gonzalez-Lamuno D, Sanchez-Barcelo EJ (2002) Does melatonin induce apoptosis in MCF−7 human breast cancer cells in vitro? J Pineal Res 32:90–96CrossRefPubMed
41.
Zurück zum Zitat Hill SM, Blask DE (1988) Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF−7) in culture. Cancer Res 48:6121–6126PubMed Hill SM, Blask DE (1988) Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF−7) in culture. Cancer Res 48:6121–6126PubMed
42.
Zurück zum Zitat Kanishi Y, Kobayashi Y, Noda S, Ishizuka B, Saito K (2000) Differential growth inhibitory effect of melatonin on two endometrial cancer cell lines. J Pineal Res 28:227–233CrossRefPubMed Kanishi Y, Kobayashi Y, Noda S, Ishizuka B, Saito K (2000) Differential growth inhibitory effect of melatonin on two endometrial cancer cell lines. J Pineal Res 28:227–233CrossRefPubMed
43.
Zurück zum Zitat Mediavilla MD, Cos S, Sanchez-Barcelo EJ (1999) Melatonin increases p53 and p21WAF1 expression in MCF−7 human breast cancer cells in vitro. Life Sci 65:415–420CrossRefPubMed Mediavilla MD, Cos S, Sanchez-Barcelo EJ (1999) Melatonin increases p53 and p21WAF1 expression in MCF−7 human breast cancer cells in vitro. Life Sci 65:415–420CrossRefPubMed
44.
Zurück zum Zitat Petranka J, Baldwin WS, Bierman J, Jayadev S, Barrett JC, Murphy E (1999) The oncostatic action of melatonin in an ovarian carcinoma cell line. Pineal Res 26:129–136 Petranka J, Baldwin WS, Bierman J, Jayadev S, Barrett JC, Murphy E (1999) The oncostatic action of melatonin in an ovarian carcinoma cell line. Pineal Res 26:129–136
45.
Zurück zum Zitat Shiu SY, Li L, Xu JN, Pang CS, Wong JT, Pang SF (1999) Melatonin-induced inhibition of proliferation and G1/S cell cycle transition delay of human choriocarcinoma JAr cells: possible involvement of MT2 (MEL1B) receptor. Pineal Res 27:183–192 Shiu SY, Li L, Xu JN, Pang CS, Wong JT, Pang SF (1999) Melatonin-induced inhibition of proliferation and G1/S cell cycle transition delay of human choriocarcinoma JAr cells: possible involvement of MT2 (MEL1B) receptor. Pineal Res 27:183–192
46.
Zurück zum Zitat Sze SF, Ng TB, Liu WK (1993) Antiproliferative effect of pineal indoles on cultured tumor cell lines. J Pineal Res 14:27–33PubMed Sze SF, Ng TB, Liu WK (1993) Antiproliferative effect of pineal indoles on cultured tumor cell lines. J Pineal Res 14:27–33PubMed
47.
Zurück zum Zitat Ying SW, Niles LP, Crocker C (1993) Human malignant melanoma cells express high-affinity receptors for melatonin: antiproliferative effects of melatonin and 6-chloromelatonin. Eur J Pharmacol 246:89–96PubMed Ying SW, Niles LP, Crocker C (1993) Human malignant melanoma cells express high-affinity receptors for melatonin: antiproliferative effects of melatonin and 6-chloromelatonin. Eur J Pharmacol 246:89–96PubMed
48.
Zurück zum Zitat Tamarkin L, Cohen M, Roselle D, Reichert C, Lippman M, Chabner B (1981) Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. Cancer Res 41:4432–4436PubMed Tamarkin L, Cohen M, Roselle D, Reichert C, Lippman M, Chabner B (1981) Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. Cancer Res 41:4432–4436PubMed
49.
Zurück zum Zitat Musatov SA, Anisimov VN, Andre V, Vigreux C, Godard T, Sichel F (1999) Effects of melatonin on N-nitroso-N-methylurea-induced carcinogenesis in rats and mutagenesis in vitro (Ames test and COMET assay).Cancer Lett 138:37–44CrossRefPubMed Musatov SA, Anisimov VN, Andre V, Vigreux C, Godard T, Sichel F (1999) Effects of melatonin on N-nitroso-N-methylurea-induced carcinogenesis in rats and mutagenesis in vitro (Ames test and COMET assay).Cancer Lett 138:37–44CrossRefPubMed
50.
Zurück zum Zitat Anisimov VN, Popovich IG, Zabezhinski MA (1997) Melatonin and colon carcinogenesis: I. Inhibitory effect of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats. Carcinogenesis 18:1549–1553CrossRefPubMed Anisimov VN, Popovich IG, Zabezhinski MA (1997) Melatonin and colon carcinogenesis: I. Inhibitory effect of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats. Carcinogenesis 18:1549–1553CrossRefPubMed
51.
Zurück zum Zitat Anisimov VN, Kvetnoy IM, Chumakova NK, et al. (1999) Melatonin and colon carcinogenesis. Exp Toxicol Pathol 51:47–52PubMed Anisimov VN, Kvetnoy IM, Chumakova NK, et al. (1999) Melatonin and colon carcinogenesis. Exp Toxicol Pathol 51:47–52PubMed
52.
Zurück zum Zitat Cini G, Coronnello M, Mini E, Neri B (1998) Melatonin’s growth-inhibitory effect on hepatoma AH 130 in the rat. Cancer Lett 125:51–59CrossRefPubMed Cini G, Coronnello M, Mini E, Neri B (1998) Melatonin’s growth-inhibitory effect on hepatoma AH 130 in the rat. Cancer Lett 125:51–59CrossRefPubMed
53.
Zurück zum Zitat Mocchegiani E, Perissin L, Santarelli L, et al. (1999) Melatonin administration in tumor-bearing mice (intact and pinealectomized) in relation to stress, zinc, thymulin and IL−2. Int J Immunopharmacol 21:27–46PubMed Mocchegiani E, Perissin L, Santarelli L, et al. (1999) Melatonin administration in tumor-bearing mice (intact and pinealectomized) in relation to stress, zinc, thymulin and IL−2. Int J Immunopharmacol 21:27–46PubMed
55.
Zurück zum Zitat Blask DE, Dauchy RT, Sauer LA, Krause JA, Brainard GC (2002) Light during darkness, melatonin suppression and cancer progression. Neuroendocrinol Lett 23:52–56PubMed Blask DE, Dauchy RT, Sauer LA, Krause JA, Brainard GC (2002) Light during darkness, melatonin suppression and cancer progression. Neuroendocrinol Lett 23:52–56PubMed
56.
Zurück zum Zitat Dauchy RT, Blask DE, Sauer LA, Brainard GC, Krause JA (1999) Dim light during darkness stimulates tumor progression by enhancing tumor fatty acid uptake and metabolism. Cancer Letters 144:131–136CrossRefPubMed Dauchy RT, Blask DE, Sauer LA, Brainard GC, Krause JA (1999) Dim light during darkness stimulates tumor progression by enhancing tumor fatty acid uptake and metabolism. Cancer Letters 144:131–136CrossRefPubMed
57.
Zurück zum Zitat Vijayalaxmi, Thomas CRJ, Reiter RJ, Herman TS (2002) Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 20:2575–2601CrossRefPubMed Vijayalaxmi, Thomas CRJ, Reiter RJ, Herman TS (2002) Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 20:2575–2601CrossRefPubMed
58.
Zurück zum Zitat Schernhammer ES, Hankinson SE (2003) Light at night: a novel risk factor for cancer in shift workers? Clin Occupational Environment Med 3:263–278 Schernhammer ES, Hankinson SE (2003) Light at night: a novel risk factor for cancer in shift workers? Clin Occupational Environment Med 3:263–278
59.
Zurück zum Zitat Snyder SH, Axelrod J, Zweig M (1967) Circadian rhythm in the serotonin content of the rat pineal gland: regulating factors. J Pharmacol Exp Ther 158:206–213PubMed Snyder SH, Axelrod J, Zweig M (1967) Circadian rhythm in the serotonin content of the rat pineal gland: regulating factors. J Pharmacol Exp Ther 158:206–213PubMed
60.
Zurück zum Zitat Zeitzer JM, Dijk DJ, Kronauer R, Czeisler C (2000) Sensitivity of the human circadian pacemaker to nocturnal light: melatonin phase resetting and suppression. J Physiol 526:695–702PubMed Zeitzer JM, Dijk DJ, Kronauer R, Czeisler C (2000) Sensitivity of the human circadian pacemaker to nocturnal light: melatonin phase resetting and suppression. J Physiol 526:695–702PubMed
61.
Zurück zum Zitat Graham C, Cook MR (2001) Examination of the melatonin hypothesis in women exposed at night to EMF or bright light. Environ Health Perspect 109:501–507PubMed Graham C, Cook MR (2001) Examination of the melatonin hypothesis in women exposed at night to EMF or bright light. Environ Health Perspect 109:501–507PubMed
62.
Zurück zum Zitat Davis S, Mirick DK, Stevens RG (2001) Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 93:1557–1562PubMed Davis S, Mirick DK, Stevens RG (2001) Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 93:1557–1562PubMed
63.
Zurück zum Zitat Hansen J (2001) Increased breast cancer risk among women who work predominantly at night. Epidemiology 12:74–77CrossRefPubMed Hansen J (2001) Increased breast cancer risk among women who work predominantly at night. Epidemiology 12:74–77CrossRefPubMed
64.
Zurück zum Zitat Pukkala E, Auvinen H, Wahlberg G (1995) Incidence of cancer among Finnish airline cabin attendants. BMJ 311:649–652PubMed Pukkala E, Auvinen H, Wahlberg G (1995) Incidence of cancer among Finnish airline cabin attendants. BMJ 311:649–652PubMed
65.
Zurück zum Zitat Rafnsson V, Tulinius H, Jonasson JG, Hrafnkelsson J (2001) Risk of breast cancer in female flight attendants: a population-based study (Iceland). Cancer Causes and Control 12:95–101 Rafnsson V, Tulinius H, Jonasson JG, Hrafnkelsson J (2001) Risk of breast cancer in female flight attendants: a population-based study (Iceland). Cancer Causes and Control 12:95–101
66.
Zurück zum Zitat Schernhammer ES, Laden F, Speizer FE, et al. (2001) Rotating night shifts and risk of breast cancer in women participating in the Nurses’ Health Study. J Natl Cancer Inst 93:1563–1568PubMed Schernhammer ES, Laden F, Speizer FE, et al. (2001) Rotating night shifts and risk of breast cancer in women participating in the Nurses’ Health Study. J Natl Cancer Inst 93:1563–1568PubMed
67.
Zurück zum Zitat Tynes T, Hannevik M, Andersen A, Vistnes A, Haldorsen T (1996) Incidence of breast cancer in Norwegian female radio and telegraph operators. Cancer Cause Control 7:197–204CrossRef Tynes T, Hannevik M, Andersen A, Vistnes A, Haldorsen T (1996) Incidence of breast cancer in Norwegian female radio and telegraph operators. Cancer Cause Control 7:197–204CrossRef
68.
Zurück zum Zitat Ballard T, Lagorio S, De Angelis G, Verdecchia A (2000) Cancer incidence and mortality among flight personnel: a meta-analysis. Aviat Space Environ Med 71:216–224PubMed Ballard T, Lagorio S, De Angelis G, Verdecchia A (2000) Cancer incidence and mortality among flight personnel: a meta-analysis. Aviat Space Environ Med 71:216–224PubMed
69.
Zurück zum Zitat Mawson AR (1998) Breast cancer in female flight attendants.Lancet 352:626PubMed Mawson AR (1998) Breast cancer in female flight attendants.Lancet 352:626PubMed
70.
Zurück zum Zitat Whelan EA (2003) Cancer incidence in airline cabin crew. Occup Environ Med 60:805–806PubMed Whelan EA (2003) Cancer incidence in airline cabin crew. Occup Environ Med 60:805–806PubMed
71.
Zurück zum Zitat Schernhammer E, Kroenke C, Laden F, Hankinson S (2005) Night work and melatonin levels in women participating in the Nurses’ Health Study II: Associate with breast cancer risk. In: 2nd Symposium of the Dana-Farber/Harvard Cancer Center Program in Breast Cancer, 2005, Boston Schernhammer E, Kroenke C, Laden F, Hankinson S (2005) Night work and melatonin levels in women participating in the Nurses’ Health Study II: Associate with breast cancer risk. In: 2nd Symposium of the Dana-Farber/Harvard Cancer Center Program in Breast Cancer, 2005, Boston
72.
Zurück zum Zitat Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH (1995) Occurrence of different cancers in patients with Parkinson’s disease. BMJ 310:1500–1501PubMed Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH (1995) Occurrence of different cancers in patients with Parkinson’s disease. BMJ 310:1500–1501PubMed
73.
Zurück zum Zitat Anton-Tay F, Diaz JL, Fernandez-Guardiola A (1971) On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sci I 10:841–850PubMed Anton-Tay F, Diaz JL, Fernandez-Guardiola A (1971) On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sci I 10:841–850PubMed
74.
Zurück zum Zitat Fertl E, Auff E, Doppelbauer A, Waldhauser F (1991) Circadian secretion pattern of melatonin in Parkinson’s disease. J Neural Transm Park Dis Dement Sect 3:41–47CrossRefPubMed Fertl E, Auff E, Doppelbauer A, Waldhauser F (1991) Circadian secretion pattern of melatonin in Parkinson’s disease. J Neural Transm Park Dis Dement Sect 3:41–47CrossRefPubMed
75.
Zurück zum Zitat Struppler A, Velbo-Groneberg P, Claussen M (1976) Clinic and pathophysiology of tremor In: Birkmayer W, Hornykiewicz O, (eds) Advances in Parkinsonism. Editions Roche, Basel, pp 287 Struppler A, Velbo-Groneberg P, Claussen M (1976) Clinic and pathophysiology of tremor In: Birkmayer W, Hornykiewicz O, (eds) Advances in Parkinsonism. Editions Roche, Basel, pp 287
Metadaten
Titel
Circulating Melatonin Levels: Possible Link Between Parkinson’s Disease and Cancer Risk?
verfasst von
Eva Schernhammer
Honglei Chen
Beate Ritz
Publikationsdatum
01.05.2006
Verlag
Kluwer Academic Publishers
Erschienen in
Cancer Causes & Control / Ausgabe 4/2006
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-005-9002-9

Weitere Artikel der Ausgabe 4/2006

Cancer Causes & Control 4/2006 Zur Ausgabe

Special Section on Cancer and Rhythm

Cancer and Rhythm

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.